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Abstract
Objective. The efficacy of programmes to reduce long-term benzodiazepine use could be compromised by subsequent
increases in contacts with the family practice. In this study the hypothesis was tested as to whether participation in a
benzodiazepine discontinuation programme affects the frequency of contacts with the family practice. Design. A controlled
stepped-care intervention programme to decrease long-term benzodiazepine use. Setting. Family practices in the
Netherlands. Subjects. The experimental group consisted of 996 long-term benzodiazepine users and a control group of
883 long-term benzodiazepine users. Main outcome measures. Practice contacts before and up to 12 months after the start of
the programme. Results. There was a general tendency visible for contacts to decrease during the follow-up time. The course
of the number of contacts during the follow-up was not different for the experimental and control groups (p0.45). The
level of non-benzodiazepine prescriptions was generally not altered. The number of non-benzodiazepine prescriptions
decreased in benzodiazepine quitters during the follow-up of the programme. Conclusion. No clinically important differences
in practice contacts were observed when the course of the number of contacts and non-benzodiazepine prescriptions were
compared between the experimental and control groups. Family practitioners do not have to anticipate an increased
workload associated with participation in such a benzodiazepine discontinuation programme.
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Long-term use of benzodiazepines remains wide-
spread, irrespective of national and international
guidelines advising short-term use [14]. Patient-
as well as physician-related factors may be respon-
sible for the initiation and persistence of this
prescribing practice [5,6]. It appears that physicians
and patients think differently about the therapeutic
efficacy and risks of using benzodiazepines [7].
Long-term users of benzodiazepines often mention
high treatment satisfaction without being very con-
cerned about the side effects [8]. On the other hand,
many physicians perceive that the chances for long-
term benzodiazepine users to quit their use are small
[9]. Furthermore, family practitioners anticipate
difficulties in persuading patients to withdraw and
suppose that quitting benzodiazepine use will in-
crease other patient demands as a substitution
[9,10]. These opinions may prevent family practi-
tioners from taking an active role in addressing this
subject with their patients. Within a study aimed at
the reduction of long-term benzodiazepine use in
family practice in the Netherlands, the Benzoredux
study [11,12], we had the opportunity to test the
hypothesis as to whether participation in a benzo-
diazepine discontinuation programme affects the
frequency of contacts with the family practice.
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Material and methods
The Benzoredux study (source population)
The Benzoredux study was a family practice based
prospective controlled study. It used a stepped
intervention with a benzodiazepine discontinuation
letter as the first step, followed by the second step: a
three-group randomized clinical trial with a guided
taper programme, with or without additional group
psychotherapy, or usual care [11,12]. The long-term
benzodiazepine users received benzodiazepine pre-
scriptions for more than three months. In 30 family
practices 2964 long-term benzodiazepine users were
identified. After applying exclusion criteria, 2004
were included. Three months after the discontinua-
tion letter subjects were invited to make an appoint-
ment with the family practitioner (FP) for an
evaluation consultation. Of the subjects that still
used benzodiazepines and had an evaluation con-
sultation (n1036), 180 gave informed consent and
were randomized in step 2 [12]. From the Dutch
National Information Network of Family Practices
(LINH), 19 practices were selected as control
practices (long-term users, n2061) [13]. Six
months after the discontinuation letter 24% of the
long-term users in the participating practices had no
more benzodiazepine prescriptions [11]. In the
second step, of the subjects receiving taper, 61%
discontinued benzodiazepine use [12].
Study population
From the participating practices of the Benzoredux
study, six practices (three experimental and three
control) had insufficient data follow-up. From the
remaining practices (27 experimental and 16 con-
trol), those practices were selected that used PRO-
MEDICOTM as electronic medical dossier (EMD)
[14]. Eleven experimental practices (n996) and
nine control practices (n883) complied with this
criterion (Figure 1).
Variables
The following data were extracted anonymously
from the EMD: (1) demographic data, (2) prescrip-
tions, and (3) dates and administration codes of
handlings, operations, financial declarations, con-
sultations, diagnostic reports, referral, etc.
Practice contacts, defined as a notification in the
EMD, were classified in six types. In hierarchical
sequence: (1) home visit, (2) consultation, (3)
telephone contact, (4) (practice) assistant contact
(for instance, diagnostic operations like urine checks
and treatment operations such as vaccination), (5)
other contact (any other non-specified notification),
and (6) a prescription line without any other
notification in the EMD (‘‘separate prescription
line’’).
We dichotomized contacts per day into ‘‘yes’’ or
‘‘no contact’’. If more contact types were present on
the same day, we recorded the contact with the
highest ranking according to the hierarchical se-
quence mentioned above. In the experimental prac-
tices the intervention started at the moment when
the discontinuation letter was sent. To rule out
seasonal differences, a similar starting date was
applied for the control practices (matched by date
at the level of practice). Baseline was defined as
the period of three months before the start of the
intervention. The 12-month follow-up was divided
into four subsequent periods of three months
(periods 14).
Analysis
We compared the course of the number of contacts
in the experimental group with the control group.
The experimental group (n996 long-term benzo-
diazepine users) contained the subjects that were
addressed by the discontinuation letter (n687) and
those who were not (n309) (see Figure 1). A
‘‘quitter’’ was defined as a subject who did not
receive any benzodiazepine prescription in the sec-
ond follow-up period (months 4 up to and including
6) [11]. We used a Poisson regression model with
correction for over-dispersion (GENMOD proce-
dure in SAS) [15] with number of contacts (or
prescriptions) as the dependent variable. There were
five time points: baseline and four three-month
periods. Apart from the variables ‘‘group’’ (experi-
mental/control), ‘‘time’’ (five time points) and their
interaction term, we entered the following co-vari-
ables in the analysis: ‘‘health insurance’’ (NHS or
Whether intervening with long-term benzodia-
zepine use may lead to subsequent increases in
other patient demands is not clear.
. Participation in a benzodiazepine discon-
tinuation programme did not increase the
number of family practice contacts by long-
term benzodiazepine users.
. Family practitioners do not have to antici-
pate an increased workload as a spin-off of
the reported benzodiazepine discontinua-
tion programme.
. This finding removes a possible obstacle for
implementation of this successful benzodia-
zepine discontinuation strategy.
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private), ‘‘gender’’ (M/F), ‘‘baseline benzodiazepine
use’’ (number of prescribed daily standard dosages
(PDD) in the baseline period), ‘‘number of baseline
non-benzodiazepine prescriptions’’ (number of non-
benzodiazepine prescriptions in the baseline period),
and ‘‘age’’ (year). The statistical significance of the
estimate of the interaction term between the group
(experimental or control) and time provided the
information on whether there was a difference in the
course of the number of contacts (or prescriptions)
during the follow-up between the experimental and
control groups.
We analysed prescription separately from con-
tacts in two different categories: benzodiazepine
prescriptions and non-benzodiazepine prescriptions.
Furthermore, we analysed practice contacts also
without prescriptions (‘‘prescription excluded con-
tacts’’). In order to establish whether benzodiaze-
pine quitters had a different course of contacts
compared with non-quitters, we entered the vari-
ables ‘‘quitter’’ (yes/no), ‘‘time’’ and their interaction
term in a model with ‘‘health insurance’’, ‘‘gender’’,
‘‘baseline benzodiazepine use’’, ‘‘number of baseline
non-benzodiazepine prescriptions’’, and ‘‘age’’ as
covariates. Separate analysis was performed in the
control group, the experimental group, and the pure
intervention group (those subjects actually receiving
the discontinuation letter).
In all analysis comparisons were made for subjects
with a complete follow-up. Two sided p-values were
used with a significance level of 0.05.
Results
Baseline characteristics
The distribution of the demographic variables com-
pared favourably, as well between the study popula-
tion and the source population as between the
experimental and the control condition (Table I).
Contacts
The average numbers of contacts per three-month
period in the experimental and control groups are
given in Table II. The number of practice contacts
(SD) per three months varied between 5.7 (4.3) and
6.3 (4.2) in the experimental group and 6.4 (4.8)
Discontinuation
letter (687) 
No discontinuation
letter (309) 
Dose reduction trial  (50) 
-Taper + psychotherapy (21) 
-Taper alone (19)
-Usual care (10)
-in psychiatric treatment (113)
-drug/alcoh. dependency (28)
-psychosis in med. history (30)
-epilepsy (18)
-terminal disease (8)
-not mastering Dutch (13)
-other individual FP reasons (99)1
End of follow-up at 12 months
996 883Study population
Source population Experimental group
N=2425
Control group
N=1821
Different EMD
1252   +  702
Step 1
Step 2
N=996 N=883
Complete follow -up
N=2248 
Complete follow-up
N=1585 
No dose reduction
trial  (637) 
Lost to follow-up
177   + 236
Figure 1. Flow diagram. 1‘‘Other individual FP reasons’’ refers to those exclusions made at the specific instigation of the FP for individual
reasons of comorbidity, psychosocial reasons, high age, severe disability, currently not in the practice.
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and 6.9 (4.9) in the control group. There was a
general tendency visible for contacts to decrease
during follow-up. The course of the number of
contacts during the follow-up was not different for
the experimental and control groups (p0.45).
Quitters had lower contacts and showed a larger
decrease in contacts compared with non-quitters
(pB0.001). When prescriptions were excluded from
the counting of contacts, the course of contacts was
not different for the experimental and control groups
(p0.06), but statistically different for quitters and
non-quitters (p0.04). The course of the number
of consultations was statistically different for the
experimental group compared with the control
group (p0.002). This was due to an increase in
consultations in the experimental group relative to
the control group in the first two three-month
periods (comparison with baseline and period 1:
p0.002; period 2: pB0.001; period 3: p0.10;
period 4: p0.22). The course of the number of
consultations was statistically different for the quit-
ters and non-quitters (p0.02), where quitters had
fewer consultations compared with the non-quitters.
The analysis of the course of the number of
consultations in the control, experimental, and
pure intervention groups separately showed no
statistically significant difference between quitters
and non-quitters (control group: p0.23; experi-
mental group: p0.10; pure intervention group:
p0.14).
Table I. Charateristics of study subjects.
Source population Study population
Control Experimental Control Experimental
Number of practices 16 27 9 11
Number of long-term users 1821 2425 883 996
Age (years) (mean(SD)) 65 (16) 62 (15) 65 (15) 61 (15)
Gender (% female) 73 71 72 69
Health insurance (% NHS) 80 80 83 84
Discontinuation programme 0 70% 0 69%
Baseline daily average of BZ1 prescription in DDD (SD)2 0.8 (0.8) 0.9 (1.0) 0.8 (0.7) 0.9 (1.1)
Complete BZ discontinuation at six months 12% 24% 12% 24%
Notes: 1BZbenzodiazepine; 2counted by using benzodiazepine equivalence rules by Zitman and Couve´e [16].
Table II. Average number of contacts (SD) per three-month period in the experimental group (n996) and the control group (n883).
Follow-up
Baseline
30 months
Period 1
03 months
Period 2
46 months
Period 3
79 months
Period 4
1012 months
Practice contacts
Experimental 6.2 (4.4) 6.3 (4.2) 6.1 (4.4) 5.7 (4.4) 5.7 (4.3)
Non-quitters (n752) 6.6 (4.7) 6.7 (4.2) 6.9 (4.4) 6.1 (4.6) 6.3 (4.5)
Quitters (n244) 5.2 (3.1) 5.1 (3.9) 4.4 (3.8) 4.3 (3.3) 4.0 (3.3)
Control 6.8 (5.0) 6.9 (4.9) 6.6 (5.0) 6.4 (4.9) 6.4 (4.8)
Non-quitters (n779) 7.0 (5.0) 7.2 (5.0) 7.0 (5.0) 6.7 (5.0) 6.7 (4.9)
Quitters (n104) 5.4 (4.0) 5.1 (4.0) 3.9 (3.5) 4.2 (3.5) 3.8 (3.6)
Prescription excluded contacts
Experimental 2.3 (2.9) 2.6 (2.7) 2.5 (2.7) 2.1 (2.8) 2.2 (2.7)
Non-quitters (n752) 2.3 (3.1) 2.6 (2.7) 2.6 (2.8) 2.2 (3.0) 2.4 (2.9)
Quitters (n244) 2.0 (2.2) 2.4 (2.8) 2.1 (2.2) 2.0 (2.1) 1.7 (2.2)
Control 2.7 (3.3) 2.9 (2.9) 2.6 (3.1) 2.4 (2.9) 2.5 (2.9)
Non-quitters (n779) 2.7 (3.2) 2.9 (2.9) 2.6 (3.1) 2.5 (2.9) 2.5 (2.9)
Quitters (n104) 2.8 (3.3) 2.7 (2.9) 2.1 (2.4) 2.1 (2.6) 2.0 (2.5)
Consultations
Experimental 0.9 (1.5) 1.0 (1.5) 1.1 (1.5) 1.0 (1.5) 0.9 (1.5)
Non-quitters (n752) 0.9 (1.5) 1.0 (1.5) 1.2 (1.5) 1.0 (1.5) 0.9 (1.6)
Quitters (n244) 0.9 (1.3) 1.0 (1.5) 1.0 (1.3) 0.9 (1.3) 0.7 (1.0)
Control 1.1 (1.7) 0.9 (1.4) 1.0 (1.4) 1.0 (1.5) 1.0 (1.4)
Non-quitters (n779) 1.1 (1.7) 0.9 (1.4) 1.1 (1.5) 1.0 (1.5) 1.0 (1.4)
Quitters (n104) 1.2 (1.7) 1.0 (1.4) 0.9 (1.1) 0.8 (1.0) 0.9 (1.0)
Benzodiazepine discontinuation programme 77
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Prescriptions
The average numbers of prescriptions per three-
month period in the experimental and control
groups are given in Table III. The number of non-
benzodiazepine prescriptions (SD) per three months
varied between 6.0 (5.7) and 5.6 (5.6) in the
experimental group and 6.6 (6.8) and 6.1 (6.7) in
the control group. The level of non-benzodiazepine
prescriptions was generally not altered. The differ-
ences in course of number of non-benzodiazepine
prescriptions between the experimental and control
groups were not statistically significant (p0.96),
but were statistically significant for benzodiazepines
(pB0.001).
Although the level of non-benzodiazepine pre-
scriptions was stable in non-quitters, quitters, in
both the experimental and the control groups,
showed a decrease in number of non-benzodiazepine
prescriptions during the follow-up. The decrease in
non-benzodiazepine prescriptions of quitters was
statistically different compared with non-quitters in
all subjects (pB0.001), the experimental group
subjects (p0.001) and in the pure intervention
group (p0.01), but not in the control group
subjects (p0.18).
Other contacts
At baseline, in the experimental group, the mean
number of home visits was 0.27 (SD 0.99), the
mean number of telephone consultations was 0.17
(SD 0.89), the mean number of practice assistant
contacts was 0.07 (SD 0.26), and other 0.82 (SD
1.21). These numbers were statistically not different
from the baseline values of the control group: home
visits 0.46 (SD 1.38; p0.12), telephone contacts
0.14 (SD 0.63; p0.99), assistant contacts 0.17
(SD 0.46; p0.43) and other 0.84 (SD 1.36; p
0.74). During follow-up these numbers did not
change significantly.
Discussion
The most important finding of this study was that
the course of the number of both non-benzodiaze-
pine prescriptions and practice contacts excluding
separate prescriptions was not relevantly influenced
by participation in this benzodiazepine reduction
programme. Moreover, benzodiazepine quitters
showed a larger decrease in contacts and non-
benzodiazepine prescriptions, compared with non-
quitters. These observations clearly do not support
the hypothesis that quitting benzodiazepine use will
increase other patient demands as a substitution
[9,10].
In our data analysis, we generally made two
comparisons. First, we compared the experimental
group with the control group. This is methodologi-
cally the most valid comparison, thereby accepting a
loss of specificity due to the fact that about one-third
of the experimental group subjects were excluded
from the intervention. The second comparison,
Table III. Average number of prescriptions1 (SD) per three-month period in the experimental group (n996) and the control group
(n883).
Follow-up
Baseline
30 months
Period 1
03 months
Period 2
46 months
Period 3
79 months
Period 4
1012 months
Benzodiazepine prescriptions
Experimental 3.0 (2.2) 2.4 (2.5) 2.3 (2.5) 2.3 (2.5) 2.2 (2.4)
Non-quitters (n752) 3.3 (2.4) 2.9 (2.5) 3.0 (2.5) 2.9 (2.6) 2.8 (2.5)
Quitters (n244) 2.0 (1.4) 0.7 (1.0) 0.0 (0.0) 0.4 (0.8) 0.4 (0.9)
Control 2.8 (2.2) 2.6 (2.2) 2.6 (2.5) 2.5 (2.5) 2.4 (2.2)
Non-quitters (n779) 2.9 (2.3) 2.8 (2.2) 2.9 (2.4) 2.7 (2.5) 2.7 (2.2)
Quitters (n104) 2.0 (1.3) 1.2 (1.2) 0.0 (0.0) 0.6 (1.2) 0.5 (0.9)
Non-benzodiazepine prescriptions
Experimental 5.6 (5.5) 6.0 (5.7) 5.6 (5.7) 5.7 (6.0) 5.6 (5.6)
Non-quitters (n752) 5.8 (5.8) 6.2 (6.0) 6.0 (6.0) 6.0 (6.4) 6.0 (5.9)
Quitters (n244) 4.7 (4.5) 5.1 (4.8) 4.4 (4.4) 4.7 (4.3) 4.1 (4.0)
Control 6.1 (6.6) 6.6 (6.8) 6.2 (6.7) 6.1 (6.7) 6.1 (6.3)
Non-quitters (n779) 6.3 (6.7) 6.8 (7.0) 6.5 (6.9) 6.4 (6.8) 6.4 (6.5)
Quitters (n104) 4.5 (4.7) 4.7 (4.7) 3.8 (4.3) 4.1 (5.2) 3.8 (4.0)
Notes: 1Average number of prescriptions refers to the average number of all prescriptions per subject in a three-month period. Contrary to
the counting of contacts, where only one contact a day was counted in the sum there was no such restriction in counting prescriptions: all
separate prescriptions of all agents were counted.
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between quitters and non-quitters, should be inter-
preted with caution as quitters probably constitute a
selected group.
This study was not primarily set up for the
measuring of practice contacts. We composed prac-
tice contacts afterwards using all information avail-
able in the EMD, including clinical, administration,
and financial data, and all prescriptions. We are
confident of our measurement as only on the rare
occasion that, for a contact, nothing was entered in
the EMD, we missed it. We had very large samples.
A power estimation, made afterwards, suggested the
study had power (beta 0.2) to detect a difference of
5% in overall contacts. This was in our opinion
sufficient. Regression to the mean effects may be
responsible for part of the decrease in the number of
benzodiazepine prescriptions. However, these effects
do not invalidate our comparison as they appear in
both the experimental and the control group. Differ-
ences in timing of data acquisition might have
invalidated the comparison of the lost to follow-up
groups. Therefore, we decided to analyse study
completers only. We do not consider that the
intervention itself caused a substantial migration of
patients, as the presentation of the intervention by
the family practitioner was not compulsory.
We did observe a statistically significant increase in
number of consultations in only the first six months
in the experimental group. Quitters had fewer
consultations than non-quitters. This suggests that
it was a temporary effect related to the positioning of
evaluation consultations for which the subjects were
invited around three months after the discontinua-
tion letter. As these consultations were used also for
other encounter reasons, we could not filter them
out in the counting of contacts.
Our analysis of family practice contacts is unique.
Only one earlier, much smaller, study reported no
change in the number of consultations in the first six
months after a brief intervention to reduce chronic
use of benzodiazepines [17].
We conclude that this benzodiazepine disconti-
nuation programme does not increase family practice
contacts. This contradicts expectations of family
practitioners that discourage them from starting
benzodiazepine discontinuation interventions. These
expectations may be based too often on experiences
with individual patients but appear to be not valid for
the whole group of long-term benzodiazepine users.
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